CYLERT
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Jan 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLERT is an oral small-molecule tablet (including chewable formulation) approved in 1976 by Abbott. The drug's specific mechanism of action, pharmacologic class, and approved indications are not documented in available data. This product represents a legacy small-molecule therapy now in late lifecycle stages.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%) suggests contracted team and transition-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching loss of exclusivity indicate CYLERT is a consolidation/wind-down assignment rather than a growth opportunity. Professionals on this product may focus on transition planning, generic readiness, and cost management rather than market expansion.
Brand ManagerField Sales Representative
Worked on CYLERT at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.